Skip to main content
BIOTRON LIMITED logo

BIOTRON LIMITED — Investor Relations & Filings

Ticker · BIT ISIN · AU000000BIT4 ASX Professional, scientific and technical activities
Open in API
Filings indexed 766 across all filing types
Latest filing 2016-11-21 Declaration of Voting R…
Country AU Australia
Listing ASX BIT

About BIOTRON LIMITED

https://www.biotron.com.au

Biotron Limited is a clinical-stage company focused on the development of novel small molecule antiviral therapeutics. The company utilizes its proprietary ViroPore technology platform to design and develop drugs that target viroporins—a class of proteins found in a wide range of viruses that play critical roles in viral replication and the evasion of host immune responses. Biotron's primary clinical program centers on BIT225, a first-in-class inhibitor targeting the HIV-1 Vpu protein and the Hepatitis C virus p7 protein. The company aims to address unmet medical needs by developing treatments that can potentially eradicate viral reservoirs and improve patient outcomes. In addition to HIV and HCV, Biotron is exploring the application of its antiviral platform against other significant viral pathogens, including SARS-CoV-2, leveraging its expertise in ion channel-targeting chemistry to disrupt the viral life cycle.

Recent filings

Filing Released Lang Actions
Results of Meeting 2 pages 32.4KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document contains the results of an Annual General Meeting (AGM) held on 22 November 2016, including voting outcomes on resolutions such as the adoption of the Remuneration Report and the re-election of a director. It also includes the Notice of the AGM with the agenda and business to be transacted. The document is short (2104 characters) and primarily reports the voting results and meeting notice rather than the full AGM materials or detailed financial reports. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2016-11-21 English
Appendix 4C - quarterly 5 pages 85.6KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B' and contains detailed financial data including consolidated statements of cash flows for the current quarter and year to date. It includes sections on cash flows from operating, investing, and financing activities, reconciliation of cash and cash equivalents, payments to directors and related parties, financing facilities, estimated cash outflows for the next quarter, and compliance statements. The presence of substantive financial data for a quarterly period and the detailed cash flow information aligns with the characteristics of an Interim / Quarterly Report. The document is not a brief announcement or a certification but a full quarterly financial report as per the Australian Stock Exchange Listing Rules. Therefore, the appropriate classification is 'IR' (Interim / Quarterly Report). The document length (8127 characters) supports it being a full report rather than a short announcement. Q1 2016
2016-10-16 English
Annual report and Notice of Annual General Meeting 55 pages 923.7KB
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT AND NOTICE OF AGM' and explicitly states it is the Company's Annual Report for the year ended 30 June 2016. The content includes detailed sections typical of an annual report such as Operating and Financial Review, Corporate Governance Statement, Directors' Report, Auditor's Report, and full financial statements. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The presence of comprehensive financial data and management discussion confirms it is the actual Annual Report, not just an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2016
2016-10-16 English
Appendix 3B 9 pages 114.3KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B - New Issue Announcement, Application for Quotation of Additional Securities' and is addressed to the ASX (Australian Securities Exchange). It details the issuance of fully paid ordinary shares, the number of securities issued, issue price, purpose of the issue, and other related information about the new securities. The document is a formal announcement of a new share issue and application for quotation of these securities on the ASX. It does not contain financial statements, management discussion, or audit information. It is not a report but an announcement related to capital changes. Therefore, the document fits the category of 'Share Issue/Capital Change' (SHA). The document length is over 12,000 characters, indicating it is a full announcement, not a brief notice or a report publication announcement.
2016-10-04 English
Change of Director's Interest Notice 3 pages 43.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references Listing Rule 3.19A, which pertains to disclosure of changes in directors' interests in securities. The content details a director's acquisition of shares and options, including dates, quantities, and transaction nature. There is no financial performance data, earnings information, or report publication. The document is a formal notification of a director's personal share transactions, fitting the definition of Director's Dealing filings.
2016-10-04 English
Clarification Statement 1 page 31.0KB
Regulatory Filings Classification · 95% confidence The document is a short letter dated 5 September 2016 from the company secretary of Biotron Limited addressed to the ASX Limited. It clarifies a previous announcement regarding the cessation of quotation for certain options on the ASX, specifying the date when trading will cease. The document is only 721 characters long and does not contain any financial data, detailed report content, or substantive analysis. It is essentially a clarification statement related to a prior announcement about a trading or quotation event. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2016-09-04 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.